soul trial oral semaglutide cardiovascular outcomes 2025 Frontiers SOUL trial: Oral semaglutide demonstrates

GLP 1 weight loss offers: Clinically proven results Reduced hunger and binge eating Improved metabolic health Better long-term adherence compared to restrictive diets This makes GLP 1 weight loss particularly appealing for people who have struggled with repeated weight-loss failures

Stay on track with check-ins and dose adjustments

It's a naturally occurring copper-binding peptide first isolated from human plasma in 1973 by biochemist Loren Pickart, who noticed that older liver tissue regenerated better when exposed to plasma from younger donors

However, when combined with insulin or sulfonylureas, hypoglycemia risk increases

That flexibility makes it a strong choice for the standard titration schedule